Gene: AR ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs6624304
rs6624304
AR
0.010 GeneticVariation BEFREE Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant. 28176139

2017
dbSNP: rs6152
rs6152
AR
0.010 GeneticVariation BEFREE To investigate the relationships between male androgenetic alopecia, androgen receptor (AR) gene polymorphism (SNP rs6152) and clinical characteristics of BPH and prostate cancer. 24665929

2015
dbSNP: rs777787518
rs777787518
AR
0.010 GeneticVariation BEFREE MDA prostate cancer 118a and MDA prostate cancer 118b cells carry a mutated β-catenin at codon 32 (D32G). 22298898

2012
dbSNP: rs139756052
rs139756052
AR
0.010 GeneticVariation BEFREE Additional studies will be required to define the frequency and contribution of the AR (A1675T) allele to early-onset and/or familial PCa in African Americans. 20173765

2010
dbSNP: rs968098233
rs968098233
AR
0.010 GeneticVariation BEFREE Although the vast majority of AR mutations appeared capable of increased activation in response to ART-27, an AR mutation identified in prostate cancer (AR P340L) and AIS (AR E2K) show reduced transcriptional responses to ART-27, whereas their response to the p160 class of coactivators was not diminished. 15919721

2005
dbSNP: rs1057519864
rs1057519864
AR
0.020 GeneticVariation BEFREE Using multiple prostate cancer cell lines, we showed that catalytic Topo II inhibitors, ICRF187 and ICRF193 inhibited transcription activities of the wild-type AR, mutant ARs (F876L and W741C) and the AR-V7 splice variant. 26009876

2015
dbSNP: rs1057519864
rs1057519864
AR
0.020 GeneticVariation BEFREE A missense mutation in the ligand-binding domain of the androgen receptor F876L confers resistance to the second-generation antiandrogens enzalutamide and ARN-509 in preclinical models of AR function and prostate cancer and is detected in plasma DNA from ARN-509-treated patients with progressive disease. 23779130

2013
dbSNP: rs976306779
rs976306779
AR
0.020 GeneticVariation BEFREE Moreover, the results confirm the oncogenic nature of S100P in prostate cancer and suggest that the protein may directly confer resistance to chemotherapy. 18452169

2008
dbSNP: rs976306779
rs976306779
AR
0.020 GeneticVariation BEFREE A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated. 15474988

2005
dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. 21177315

2011
dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk. 21177315

2011
dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223). 16039774

2005
dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223). 16039774

2005
dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002
dbSNP: rs1034866440
rs1034866440
AR
0.040 GeneticVariation BEFREE The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer. 11847524

2002
dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer. 11847524

2002
dbSNP: rs137852569
rs137852569
AR
0.040 GeneticVariation BEFREE Cytosine-adenine-guanine repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 alpha-reductase (SRD5A2) gene have been associated with prostate cancer. 12210487

2002
dbSNP: rs1340026226
rs1340026226
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852567
rs137852567
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852580
rs137852580
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852582
rs137852582
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852583
rs137852583
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852584
rs137852584
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs137852591
rs137852591
AR
0.700 GeneticVariation UNIPROT

dbSNP: rs138454018
rs138454018
AR
0.700 GeneticVariation UNIPROT